Johnson & Johnson misses revenue estimates as blockbuster drugs disappoint 
 Health and Human Services Secretary Alex Azar updates FOX Business' Lou Dobbs on the first U.S. case of coronavirus found in Washington state.




(Reuters) - Johnson  Johnson narrowly missed quarterly revenue estimates on Wednesday as sales of its blockbuster psoriasis medicine Stelara and cancer drug Imbruvica fell short of expectations.
Revenue at JJ's pharmaceuticals unit, which also makes antidepressant Spravato and plaque psoriasis drug Tremfya, rose 3.5% to $10.55 billion in the fourth quarter, missing the average estimate of $10.63 billion, according to two analysts polled by Refinitiv.
The company said it expects full-year 2020 adjusted earnings per share in the range $8.95 to $9.10.
TickerSecurityLastChangeChange %
JNJJOHNSON  JOHNSON149.27+0.10+0.07%
Litigation expenses fell to $264 million in the fourth quarter, from $1.29 billion a year ago.
CORONAVIRUS DEATH TOLL RISES TO 9 AS IT SPREADS TO HONG KONG
JJ's net earnings rose to $4.01 billion, or $1.50 per share, in the quarter, from $3.04 billion, or $1.12 per share, a year earlier.
Excluding items, it earned $1.88 per share, beating the average analyst estimate by a cent, according to IBES data from Refinitiv.
Total sales rose 1.7% to $20.75 billion, also coming in below the average estimate of $20.80 billion.
GET FOX BUSINESS ON THE GO BY CLICKING HERE
(Reporting by Manas Mishra and Saumya Sibi Joseph in Bengaluru Editing by Saumyadeb Chakrabarty)
CLICK HERE TO READ MORE ON FOX BUSINESS